Snappy newsletters. Simple Facebook sharing. Spirited comments. Sweet features are waiting… GET THEM NOW!

Bristol-Myers Makes Bid for Icahn's ImClone

Offers 29% premium for biotech partner; shares soar

By Kevin Spak,  Newser Staff

Posted Jul 31, 2008 1:21 PM CDT

(Newser) – Already a 17% shareholder, Bristol-Myers Squibb laid down a $4.5 billion offer to buy the  rest of ImClone shares, the Wall Street Journal reports. The $60-a-share offer, sent to ImClone chairman Carl Icahn today, is a 29% premium on yesterday's closing price and makes Bristol the second pharma giant to gun for its biotech partner in as many weeks.

The news sent ImClone’s stock rocketing to a four-year high of $65.36, meaning investors believe that Bristol will have to up the ante to close a deal. ImClone stock has risen more than 40% in the past year—thanks to the good buzz surrounding its Erbitux cancer treatment—but it’s still probably best known as the stock that landed Martha Stewart in jail.

In this Oct. 11, 2007 file photo, private equity investor Carl Icahn speaks at the World Business Forum in New York.
In this Oct. 11, 2007 file photo, private equity investor Carl Icahn speaks at the World Business Forum in New York.   (AP Photo/Mark Lennihan, file)
In this Oct. 11, 2007 file photo, private equity investor Carl Icahn speaks at the World Business Forum in New York.
In this Oct. 11, 2007 file photo, private equity investor Carl Icahn speaks at the World Business Forum in New York.   (AP Photo/Mark Lennihan, file)
Excedrin pain medication from Bristol-Myers Squibb is shown in this July 27, 2006 file photo in New York.
Excedrin pain medication from Bristol-Myers Squibb is shown in this July 27, 2006 file photo in New York.   (AP Photo/Mark Lennihan, file)
This undated handout photo provided by Bristol-Myers Squibb Co. shows CEO James M. Cornelius.
This undated handout photo provided by Bristol-Myers Squibb Co. shows CEO James M. Cornelius.   (AP Photo)
« Prev« Prev | Next »Next » Slideshow
To report an error on this story, notify our editors.
A snapshot of the day's best news stories.
 
COMMENTS
Be the first to comment on this story.

More Newser Stories

Pfizer Snaps Up Wyeth for $68B

Pfizer in Talks to Buy Wyeth

Icahn: Microsoft Will Only Negotiate With Me

Icahn: Yahoo Poison Pill 'Reprehensible'

Yahoo Says Icahn Doesn't Understand Full Picture


NEWS FROM OUR PARTNERS
Other Sites We Like:   24/7 Wall St.   |   Betty Confidential   |   BuzzFeed   |   Cracked   |   Fark   |   Timelines   |   The Frisky   |   Geek Sugar   |   NewsOne